Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 3, 2007, Pages 664-672

  Hitzeroth, Angelika ^a   Niehaus, Dana J H ^b   Koen, Liezl ^b   Botes, Willem C ^a   Deleuze, J F ^c   Warnich, Louise ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c SANOFI   (France)

Author keywords

Abnormal involuntary movements; MnSOD; Schizophrenia; Tardive dyskinesia; Xhosa

Indexed keywords

ALANINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; MANGANESE SUPEROXIDE DISMUTASE; NEUROLEPTIC AGENT; REACTIVE OXYGEN METABOLITE; VALINE;

ADULT; ALLELE; ANALYSIS OF COVARIANCE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INVOLUNTARY MOVEMENT; MAJOR CLINICAL STUDY; MALE; SCHIZOPHRENIA; SCORING SYSTEM; SINGLE STRAND CONFORMATION POLYMORPHISM; STATISTICAL ANALYSIS; TARDIVE DYSKINESIA; TURKEY (REPUBLIC);

ADULT; AFRICA, SOUTHERN; ALANINE; CHI-SQUARE DISTRIBUTION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; SUPEROXIDE DISMUTASE; VALINE;

EID: 33947600722     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.12.019     Document Type: Article

References (67)

1. Akyol O., Herken H., Uz E., Fadillioglu E., Unal S., Sogut S., et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalances. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 995-1005
2. Akyol O., Yanik M., Elyas H., Namli M., Canatan H., Akin H., et al. Association between Ala-9Val polymorphism of Mn-SOD gene and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 123-131
3. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl 7 (1989) 49-58
4. Andreassen O.A., and Jørgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?. Prog Neurobiol 61 (2000) 525-541
5. Andreasen N.C., Arndt S., Miller D., Flaum M., and Nopoulos P. Correlational studies of the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Positive Symptoms: an overview and update. Psychopathology 28 (1995) 7-17
6. APA. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), American Psychiatric Association, Washington, DC
7. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., et al. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry 53 (2003) 56-64
8. Arvindakshan M., Ghate M., Ranjekar P.K., Evans D.R., and Mahadik S.P. Supplementation with a combination of ω-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 62 (2003) 195-204
9. Brown K., Reid A., White T., Henderson T., Hukin S., Johnstone C., et al. Vitamin E, lipids, and lipid peroxidation products in tardive dyskinesia. Biol Psychiatry 43 (1998) 863-867
10. Cadet J.L., and Kahler L.A. Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci Biobehav Rev 18 (1994) 457-467
11. Cadet J.L., and Perumal A.S. Chronic treatment with prolixin causes oxidative stress in rat brain. Biol Psychiatry 28 (1990) 738-740
12. Chance B., Sies H., and Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev 59 (1979) 527-605
13. Chiu H., Shum P., Lau J., Lam L., and Lee S. Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong. Am J Psychiatry 149 (1992) 1081-1085
14. Chiu H., Lau J., Lam L., and Shum P. Association of negative symptoms with tardive dyskinesia in schizophrenic patients. Aust N Z J Psychiatry 27 (1993) 228-232
15. Dakhale G., Khanzode S., Khanzode S., Saoji A., Khobragade L., and Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 49 (2004) 205-209
16. Fridovich I. Superoxide dismutases. Adv Enzymol Relat Areas Mol Biol 41 (1974) 35-97
17. Fridovich I. Superoxide radical: an endogenous toxicant. Annu Rev Pharmacol Toxicol 23 (1983) 239-257
18. Guy W.A. Abnormal involuntary movement scale (AIMS). ECDEU Assessment Manual for Psychopharmacology (1976), US Department of Health Education and Welfare, Washington, DC 534-537
19. Halliwell B. Reactive oxygen species in living systems: source, biochemistry, and role in human disease. Am J Med 91 suppl. 3C (1991) 14S-22S
20. Halliwell B. Antioxidants and human disease: a general introduction. Nutr Rev 55 (1997) S44-S49
21. Holden T.J. Tardive dyskinesia in long-term hospitalised Zulu psychiatric patients. A prevalence study. SAMJ 71 (1987) 88-90
22. Hori H., Ohmori O., Shinkai T., Kojima H., Okano C., Suzuki T., et al. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology 23 (2000) 170-177
23. Kane J.M., and Smith J.M. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 39 (1982) 473-481
24. Kane J.M., Woerner M., and Lieberman J. Tardive dyskinesia: prevalence, incidence and risk factors. J Clin Psychopharmacol 8 suppl 4 (1988) 52S-56S
25. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., and Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 58 (2002) 1-10
26. Kimura K., Isashiki Y., Sonoda S., Kakiuchi-Matsumoto T., and Ohba N. Genetic association of manganese superoxide dismutase with exudative age-related macular degeneration. Am J Ophthalmol 130 (2000) 769-773
27. Kuloglu M., Ustundag B., Atmaca M., Canatan H., Tezcan A.E., and Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 20 (2002) 171-175
28. Lohr J.B., Kuczenski R., Bracha H.S., Moir M., and Jeste D.V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 28 (1990) 535-539
29. Lohr J.B., Caligiuri M.P., Manley M.S., and Browning J.A. Neuroleptic-induced striatal damage in rats: a study of antioxidant treatment using accelerometric and immunocytochemical methods. Psychopharmacology 148 (2000) 171-179
30. Mahadik S.P., and Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 19 (1996) 1-17
31. Mahadik S.P., Mukherjee S., Scheffer R., Correnti E.E., and Mahadik J.S. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 43 (1998) 674-679
32. Mahadik S.P., Evans D., and Lal H. Oxidative stress and role of antioxidant and ω-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 25 (2001) 463-493
33. Maurer I., and Möller H.J. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol Cell Biochem 174 (1997) 255-259
34. Melamed Y., Sirota P., Dicker D.R., and Fishman P. Superoxide anion production by neutrophils derived from peripheral blood of schizophrenia patients. Psychiatry Res 77 (1998) 29-34
35. Michel T.M., Thome J., Martin D., Nara K., Zwerina S., Tatschner T., et al. Cu, Zn- and Mn-superoxide dismutase levels in brains of patients with schizophrenic psychosis. J Neural Transm 111 (2004) 1191-1201
36. Miller M.P. Tools for Population Genetic Analyses (TFPGA) 1.3: A Windows Program for the Analysis of Allozyme and Molecular Population Genetic Data (1997). http://herb.bio.nau.edu/~miller/tfpga.htm Computer software distributed by author. http://herb.bio.nau.edu/~miller/tfpga.htm
37. Morgenstern H., and Glazer W.M. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale tardive dyskinesia study. Arch Gen Psychiatry 50 (1993) 723-733
38. 2-isoprostanes) in smokers. N Engl J Med 332 (1995) 1198-1203
39. Mukherjee S., Mahadik S.P., Scheffer R., Correnti E.E., and Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr Res 19 (1996) 19-26
40. Nurnberger Jr. J.I., Blehar M.C., Kaufmann C.A., York-Cooler C., Simpson S.G., Harkavy-Friedman J., et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 51 (1994) 849-859
41. Parikh V., Khan M.M., and Mahadik S.P. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 37 (2003) 43-51
42. Patterson B.D., Swingler D., and Willows S. Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the Eastern Cape of South Africa. Schizophr Res 76 (2004) 89-97
43. Polydoro M., Schröder N., Lima M.N., Caldana F., Laranja D.C., Bromberg E., et al. Haloperidol- and clozapine-induced oxidative stress in the rat brain. Pharmacol Biochem Behav 78 (2004) 751-756
44. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 121 (2003) 109-122
45. Rao A.V., and Balachandran B. Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr Neurosci 5 (2002) 291-309
46. Ravikumar A., Arun P., Devi K.V.D., Augustine J., and Kurup P.A. Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders. Indian J Exp Biol 38 (2000) 438-446
47. Reddy R., Keshavan M., and Yao J.K. Reduced plasma antioxidants in first episode patients with schizophrenia. Schizophr Res 62 (2003) 205-212
48. Rosenblum J.S., Gilula N.B., and Lerner R.A. On signal sequence polymorphisms and diseases of distribution. Proc Natl Acad Sci U S A 93 (1996) 4471-4473
49. Sachdev P.S. The current status of tardive dyskinesia. Aust N Z J Psychiatry 34 (2000) 355-369
50. Schooler N.R., and Kane J.M. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39 4 (1982) 486-487
51. See R.E. Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride. Neurosci Lett 129 (1991) 265-268
52. Sharma R.P. Schizophrenia, epigenetics and ligand-activated nuclear receptors: a framework for chromatin therapeutics. Schizophr Res 72 (2005) 79-90
53. Shimoda-Matsubayashi S., Matsumine H., Kobayashi T., Nakagawa-Hattori Y., Shimizu Y., and Mizuno Y. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. Biochem Biophys Res Commun 226 (1996) 561-565
54. Sirota P., Gavrieli R., and Wolach B. Overproduction of neutrophil radical oxygen species correlates with negative symptoms in schizophrenic patients: parallel studies on neutrophil chemotaxis, superoxide production and bactericidal activity. Psychiatry Res 121 (2003) 123-132
55. Sullivan P.F. The genetics of schizophrenia. PLoS Med 2 (2005) 614-618
56. 16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 13 (2003) 145-157
57. Sutton A., Imbert A., Igoudjil A., Descatoire V., Cazanave S., Pessayre D., et al. The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics 15 (2005) 311-319
58. Van Landeghem G.F., Tabatabaie P., Beckman G., Beckman L., and Andersen P.M. Manganese-containing superoxide dismutase signal sequence polymorphism associated with sporadic motor neuron disease. Eur J Neurol 6 (1999) 639-644
59. Van O., Walsh E., van Horn E., Tattan T., Bale R., Thompson S.G., and on behalf of the UK700 Group. Changes in negative symptoms and the risk of tardive dyskinesia: a longitudinal study. Acta Psychiatr Scand 101 (2000) 300-306
60. Weisiger R.A., and Fridovich I. Mitochondrial superoxide dismutase. Site of synthesis and intramitochondrial localization. J Biol Chem 248 (1973) 4793-4796
61. Wonodi I., Adami H.M., Cassady S.L., Sherr J.D., Avila M.T., and Thaker G.K. Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland Psychiatric Research Center. J Clin Psychopharmacol 24 (2004) 592-598
62. Yao J.K., Reddy R., McElhinny L.G., and van Kammen D.P. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 32 (1998) 1-8
63. Yao J.K., Reddy R., and van Kammen D.P. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 80 (1998) 29-39
64. Yao J.K., Reddy R., and van Kammen D.P. Oxidative damage and schizophrenia. An overview of the evidence and its therapeutic implications. CNS Drugs 15 (2001) 287-310
65. Zhang Z., Zhang X., Hou G., Sha W., and Reynolds G.P. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J Psychiatr Res 36 (2002) 317-324
66. Zhang X.Y., Zhou D.F., Cao L.Y., Chen D.C., Zgu F.Y., and Wu G.Y. Blood superoxide level in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res 62 (2003) 245-250
67. Zhang Z., Zhang X., Hou G., Yao H., and Reynolds G.P. Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia. Psychiatr Genet 13 (2003) 187-192